The working mechanism of the obtained TRAIL/DOX-fGO nanostructure involved both passive accumulation in the tumor due to the enhanced permeability and retention (EPR) effect and active TRAIL-directed tumor targeting, followed by the extracellular release of TRAIL after plasma membrane-located furin digestion of the peptide linker. The gene discussed is TNFSF10; the disease is neoplasm.